Scilex Holding (SCLX) Change in Inventory (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Change in Inventory of -$257000.0 for Q1 2026, down 144.01% year-over-year from $584000.0 in Q1 2025, and up 49.51% on a QoQ basis from -$509000.0 in Q4 2025.
Scilex Holding (SCLX) Change in Inventory (2022 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Change in Inventory for 5 consecutive years, with -$257000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Inventory fell 144.01% year-over-year to -$257000.0; the TTM figure through Mar 2026 stood at -$2.6 million (down 1636.84% YoY), while the FY2025 annual figure was -$1.8 million, down 23.05% from the prior year.
- Change in Inventory came in at -$257000.0 for Q1 2026 at Scilex Holding, up from -$509000.0 in the prior quarter.
- The five-year high for Change in Inventory was $897000.0 in Q1 2023, with the low at -$1.4 million in Q3 2025.
- Average Change in Inventory over 5 years is -$109647.1, with a median of -$257000.0 recorded in 2026.
- Across the five-year window, Change in Inventory soared 466.96% in 2023 and sank 1597.06% in 2025, its largest moves.
- Year by year, Change in Inventory stood at $445000.0 in 2022, then sank by 38.65% to $273000.0 in 2023, then tumbled by 87.55% to $34000.0 in 2024, then tumbled by 1597.06% to -$509000.0 in 2025, then soared by 49.51% to -$257000.0 in 2026.
- According to Business Quant data, Change in Inventory over the past three periods registered -$257000.0, -$509000.0, and -$1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 431.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 184.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -18.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 52.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -257,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -257,000.00 |
| Mar 31, 2026 | -257,000.00 |
| Dec 31, 2025 | -509,000.00 |
| Dec 31, 2025 | -509,000.00 |
| Sep 30, 2025 | -1.38 Mn |
| Sep 30, 2025 | -1.38 Mn |
| Jun 30, 2025 | -496,000.00 |
| Jun 30, 2025 | -496,000.00 |
| Mar 31, 2025 | 584,000.00 |
| Mar 31, 2025 | 584,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Sep 30, 2024 | -358,000.00 |
| Sep 30, 2024 | -358,000.00 |
| Jun 30, 2024 | -412,000.00 |
| Jun 30, 2024 | -412,000.00 |
| Mar 31, 2024 | -726,000.00 |
| Mar 31, 2024 | -726,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Dec 31, 2023 | 273,000.00 |